SynAct Pharma wins US patent appeal on resomelagon immediate-release tablet formulation

Reuters2026/08/05 13:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SynAct Pharma won a favorable U.S. PTAB appeal covering an immediate-release oral tablet formulation of resomelagon (AP1189-acetate).
The decision supports patentability versus obviousness arguments, strengthening IP protection around the company’s lead program.
SynAct previously received U.S. patents covering resomelagon’s crystal form, including one with adjusted term running to July 2, 2044.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SynAct Pharma wins US patent appeal on resomelagon immediate-release tablet formulation

You may also like

Crypto prices